Breaking news on life science and diagnostics business, policy, and funding
The clearance enables 23andMe to report on the two most common variations in the MUTYH gene influencing MAP, which increases risk of CRC development.
CMS's move to restrict coverage could limit test access for early-stage cancer patients and negatively impact lab revenues.
With its stock price languishing below $1, NantHealth has 180 days to come into compliance with Nasdaq listing rules.
PacBio is looking to increase the yield and reduce the cost of the protocol, which enables long reads and accurate sequencing.
The company has agreed to sell approximately 990,000 shares at a price of $2.25 per share, yielding about $2.2 million in gross proceeds.
Chinese state news agency Xinhua reports that a preliminary investigation has found He Jiankui performed his gene-editing work illegally.
John Mendelsohn, a former president of the University of Texas MD Anderson Cancer Center, has died, the New York Times reports.
Identical twins receive different estimates of ancestry from the same direct-to-consumer genetic testing firms, CBC reports.
In PNAS this week: chromosomal features of maize, adaptations in the vinous-throated parrotbill, and more.
This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.
